VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
XOMAPXOMA Corporation
$25.49$307M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksXOMAPFinancials

XOMA Corporation (XOMAP) Financials

30Y historyFree accessUpdated daily

The company demonstrates structural efficiency with gross margins consistently exceeding 90%, though revenue remains highly volatile, evidenced by an 83.6% sequential decline in 2025Q4.

XOMAP Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97Dec'96
Sales/Revenue27.41M52.15M28.49M4.76M6.03M38.16M29.39M18.37M5.3M52.69M5.56M55.45M18.87M35.45M33.78M58.2M33.64M98.43M67.99M84.25M29.5M18.67M3.67M24.41M29.95M17.28M6.66M2.4M6.3M18.4M3.6M
Revenue Growth %-36.12%83.06%498.72%-21.06%-84.21%29.86%59.96%246.67%-89.94%846.98%-89.97%193.9%-46.78%4.94%-41.95%72.99%-65.82%44.78%-19.31%185.62%58.01%409.39%-84.99%-18.49%73.33%159.48%177.46%-61.9%-65.76%411.11%200%
Cost of Goods Sold1.55M2.96M206K143K274K171K170K1.25M1.68M7.88M1.4M20.7M29.47M27.36M143K000000016.37M0001.87M-1.2M-1.6M-2M-2.1M
COGS % of Revenue-5.68%0.72%3.01%4.55%0.45%0.58%6.82%31.74%14.95%25.16%37.33%156.19%77.18%0.42%-------446.74%---28.07%-50%-25.4%-10.87%-58.33%
Gross Profit25.86M49.19M28.28M4.62M5.75M37.99M29.21M17.12M3.62M44.81M4.16M34.75M-10.6M8.09M33.64M58.2M33.64M98.43M67.99M84.25M29.5M18.67M-12.71M24.41M29.95M17.28M4.79M3.6M7.9M20.4M5.7M
Gross Margin %94.35%94.32%99.28%96.99%95.45%99.55%99.42%93.18%68.26%85.05%74.84%62.67%-56.19%22.82%99.58%100%100%100%100%100%100%100%-346.74%100%100%100%71.93%150%125.4%110.87%158.33%
Gross Profit Growth %-73.93%512.81%-19.78%-84.86%30.03%70.68%373.24%-91.93%976.25%-88.02%427.77%-231.05%-75.95%-42.2%72.99%-65.82%44.78%-19.31%185.62%58.01%246.91%-152.06%-18.49%73.33%260.73%33.06%-54.43%-61.27%257.89%39.02%
Operating Expenses20.89M37.8M68.26M46.46M23.17M20.46M16.8M21M20.25M32.21M62.56M91.47M100.61M93.33M85.19M92.15M100.66M81.87M106.72M86.8M70.18M54.69M81.76M81.95M62.03M44.61M34.21M48.8M50.8M37.5M34M
OpEx % of Revenue-72.49%239.61%976.52%384.39%53.62%57.17%114.33%382.05%61.13%1124.3%164.97%533.31%263.26%252.17%158.35%299.23%83.17%156.97%103.02%237.92%292.97%2230.86%335.7%207.11%258.17%513.68%2033.33%806.35%203.8%944.44%
Selling, General & Admin39.8M36.09M34.48M27.18M23.19M20.46M16.8M21M18.56M24.34M18.32M20.62M19.87M18.48M16.86M24.01M23.25M23.74M24.14M20.58M18.09M14.8M31.98M24.49M19.41M8.68M6.07M6.1M5.4M5.6M5.5M
SG&A % of Revenue-69.21%121.03%571.27%384.79%53.62%57.17%114.33%350.31%46.19%329.3%37.19%105.3%52.12%49.92%41.26%69.11%24.11%35.51%24.43%61.32%79.27%872.5%100.32%64.79%50.24%91.14%254.17%85.71%30.43%152.78%
Research & Development468K1.71M2.88M143K153K171K170K1.25M1.68M7.88M44.23M70.85M80.75M74.85M68.32M68.14M77.41M58.13M82.58M66.22M52.09M39.9M49.78M57.46M42.62M35.93M30.01M41.5M43.8M29.9M26.4M
R&D % of Revenue-3.28%10.09%3.01%2.54%0.45%0.58%6.82%31.74%14.95%795%127.78%428.01%211.14%202.25%117.08%230.11%59.06%121.46%78.59%176.6%213.7%1358.36%235.38%142.31%207.93%450.61%1729.17%695.24%162.5%733.33%
Other Operating Expenses-2M030.9M19.14M-177K-171K-170K-1.25M4.34M1.11M1.51M44K-31K-197K0082K000000000-1.87M1.2M1.6M2M2.1M
Operating Income4.97M11.38M-39.98M-41.85M-17.41M17.53M12.42M-3.88M-16.86M17.03M-61.56M-39.72M-81.83M-58.2M-56.62M-33.95M-67.1M12.96M-38.73M-2.54M-40.68M-36.02M-78.1M-57.54M-32.08M-27.33M-29.42M-45.2M-42.9M-17.1M-28.3M
Operating Margin %18.15%21.83%-140.33%-879.53%-288.93%45.94%42.25%-21.15%-318.12%32.32%-1106.36%-71.64%-433.75%-164.18%-167.62%-58.35%-199.47%13.17%-56.97%-3.02%-137.92%-192.97%-2130.86%-235.7%-107.11%-158.17%-441.75%-1883.33%-680.95%-92.93%-786.11%
Operating Income Growth %-128.48%4.47%-140.31%-199.34%41.18%419.59%76.95%-198.98%127.67%-54.96%51.46%-40.59%-2.79%-66.76%49.4%-617.78%133.46%-1422.56%93.75%-12.93%53.87%-35.73%-79.37%-17.36%7.09%34.92%-5.36%-150.88%39.58%-7.6%
EBITDA8.29M14.36M-39.76M-40.95M-17.14M17.54M12.59M-1.97M-16.83M17.34M-60.79M-38.19M-79.98M-55.63M-52.5M-28.6M-61.38M19.79M-30.61M4.19M-34.51M-30.25M-73.54M-53.55M-29.96M-26.08M-31.29M-44M-41.3M-15.1M-26.2M
EBITDA Margin %30.26%27.53%-139.57%-860.61%-284.39%45.95%42.84%-10.72%-317.55%32.9%-1092.54%-68.88%-423.92%-156.92%-155.41%-49.14%-182.46%20.11%-45.03%4.97%-117%-162.04%-2006.63%-219.35%-100.03%-150.92%-469.82%-1833.33%-655.56%-82.07%-727.78%
EBITDA Growth %123.51%136.11%2.9%-138.9%-197.74%39.31%738.98%88.29%-197.07%128.52%-59.17%52.25%-43.76%-5.96%-83.58%53.41%-410.16%164.64%-830.67%112.14%-14.09%58.87%-37.34%-78.73%-14.89%16.65%28.9%-6.54%-173.51%42.37%-11.97%
D&A (Non-Cash Add-back)3.32M2.97M216K900K274K7K172K1.92M30K304K769K1.53M1.86M2.58M4.12M5.36M5.72M6.83M8.12M6.73M6.17M5.77M4.55M3.99M2.12M1.25M-1.87M1.2M1.6M2M2.1M
EBIT38.53M11.38M-5.64M-23.46M-17.12M17.53M13.64M-63K-12.56M17.49M-49.6M-16.97M-34.02M-119.49M-66.8M-30.3M-68.38M11.16M-38.63M-2.54M-40.68M-36.02M-78.1M-57.54M-32.08M-27.33M-29.42M-45.2M-42.9M-17.2M-28.3M
Net Interest Income-12.44M-9.56M-13.84M-569K694K-461K-1.84M-1.92M-922K-1.24M-3.95M-3.77M-4.3M-4.63M-4.39M-2.46M-385K-4.84M-6.14M-7.92M-11.26M-2.37M0-1.88M00-2.68M0000
Interest Income843K3.47M00694K00000000000049K859K1.87M1.68M1.88M000000000
Interest Expense13.28M13.03M13.84M569K0461K1.84M1.92M922K1.24M3.95M4.18M4.28M4.63M4.34M2.46M385K4.89M6.89M9.78M12.93M4.25M01.88M002.68M06.5M0900K
Other Income/Expense28.94M20.43M20.5M1.02M295K-1.64M-619K1.9M3.42M-773K8.03M19.12M43.53M-65.87M-14.52M1.23M-1.63M-6.68M-6.89M-9.78M-11.16M38.81M-846K760K871K1.96M2.68M1.2M-6.5M1.5M-900K
Pretax Income33.91M31.82M-19.48M-40.83M-17.12M15.89M11.8M-1.98M-13.44M16.26M-53.53M-20.61M-38.3M-124.07M-71.14M-32.73M-68.73M6.28M-45.63M-12.33M-51.84M2.78M-77.71M-56.78M-31.21M-25.37M-26.73M-44M-49.4M-15.7M-29.2M
Pretax Margin %123.72%61.01%-68.38%-858.15%-284.04%41.64%40.15%-10.79%-253.65%30.86%-962.08%-37.16%-203.02%-349.98%-210.58%-56.24%-204.3%6.38%-67.11%-14.63%-175.74%14.9%-2120.41%-232.58%-104.2%-146.84%-401.44%-1833.33%-784.13%-85.33%-811.11%
Income Tax104K103K-5.66M0-15K91K-1.5M0-98K1.66M000-14K-74K15K27K5.73M-383K003K846K1.11M1.17M709K-4K600K4.3M-1.3M800K
Effective Tax Rate %0.31%0.32%29.05%0%0.09%0.57%-12.72%0%0.73%10.22%0%0%0%0.01%0.1%-0.05%-0.04%91.24%0.84%0%0%0.11%-1.09%-1.96%-3.75%-2.79%0.01%-1.36%-8.7%8.28%-2.74%
Net Income33.81M31.71M-13.82M-40.83M-17.1M15.8M13.3M-1.98M-13.34M14.6M-53.53M-20.61M-38.3M-124.06M-71.06M-32.74M-68.76M550K-45.24M-12.33M-51.84M2.78M-78.94M-58.65M-33.25M-28.04M-29.41M-45.8M-47.2M-15.8M-29.1M
Net Margin %123.34%60.81%-48.52%-858.15%-283.79%41.4%45.25%-10.79%-251.8%27.7%-962.08%-37.16%-203.02%-349.94%-210.36%-56.26%-204.38%0.56%-66.55%-14.63%-175.74%14.89%-2153.94%-240.26%-111.01%-162.28%-441.69%-1908.33%-749.21%-85.87%-808.33%
Net Income Growth %1282.58%329.45%66.15%-138.72%-208.27%18.8%770.94%85.15%-191.42%127.27%-159.78%46.2%69.13%-74.57%-117.04%52.38%-12601.09%101.22%-267.07%76.22%-1965.46%103.52%-34.59%-76.42%-18.57%4.66%35.78%2.97%-198.73%45.7%-29.33%
Net Income (Continuing)33.81M31.71M-13.82M-40.83M-17.1M15.8M13.3M-1.98M-13.34M14.6M-53.53M-20.61M-38.3M-124.06M-71.06M-32.74M-68.76M550K-45.24M-12.33M-51.84M2.78M-78.94M-58.65M-33.25M-28.04M-29.41M-45.8M-47.2M-15.8M-29.1M
Discontinued Operations0000000000000000000000000000000
Minority Interest0000000000000000000000000000000
EPS (Diluted)1.941.46-1.65-4.04-1.980.650.78-0.88-1.180.73-4.72-1.82-3.38-10.95-6.27-2.89-6.070.07-3.99-1.09-4.580.03-6.97-5.18-2.93-2.47-2.60-4.04-4.17-1.39-2.57
EPS Growth %468.97%188.48%59.16%-104.04%-404.62%-16.67%188.64%25.42%-261.64%115.47%-159.34%46.15%69.13%-74.64%-116.96%52.39%-8685.57%101.77%-266.06%76.2%-15366.67%100.43%-34.56%-76.79%-18.62%5%35.64%3.12%-200%45.91%-29.15%
EPS (Basic)-1.53-1.65-4.04-1.980.690.82-0.88-1.180.75-4.72-1.82-3.38-10.95-6.27-2.89-6.070.07-3.99-1.09-4.580.03-6.97-5.18-2.93-2.47-2.60-4.04-4.17-1.39-2.57
Diluted Shares Outstanding17.42M17.98M11.7M11.47M11.41M12.19M11.5M8.76M11.33M11.33M11.33M11.33M11.33M11.33M11.33M11.33M11.33M11.33M11.33M11.33M11.33M11.33M11.33M11.33M11.33M11.33M11.33M11.33M11.33M11.33M11.33M
Basic Shares Outstanding11.89M17.98M11.7M11.47M11.41M11.29M10.67M8.76M11.33M11.33M11.33M11.33M11.33M11.33M11.33M11.33M11.33M11.33M11.33M11.33M11.33M11.33M11.33M11.33M11.33M11.33M11.33M11.33M11.33M11.33M11.33M
Dividend Payout Ratio-------------------------------

Key Metrics

Growth RegimeMixed
ProfitabilityStrained
Balance SheetHealthy
Cash FlowMixed
Top Statement Risk

Lumpy Milestone Revenue Dependency

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Revenue Volatility Masks Underlying Trends

As evidenced by the quarterly data, XOMA's revenue trajectory remains highly erratic, characterized by a 83.6% sequential decline in 2025Q4 followed by a rebound, reflecting the inherent lumpiness of milestone-based payments rather than a consistent, organic growth trend across its diversified portfolio of clinical-stage royalty assets.

The reliance on transactional milestone payments creates significant quarter-over-quarter variance that complicates trend analysis. Investors should monitor whether the company can successfully transition from these one-time events to recurring, sales-based royalties, as the current revenue profile appears driven by partner-led clinical progress rather than commercial product adoption.

Structural Gross Margin Efficiency Advantage

According to the provided financial statements, XOMA consistently maintains gross margins exceeding 90%, a structural hallmark of its royalty-aggregator model where the absence of manufacturing or clinical development costs allows for nearly all top-line revenue to flow directly to the gross profit line without traditional COGS burdens.

This high-margin profile provides significant operational flexibility, yet it does not guarantee bottom-line profitability due to the substantial G&A expenses required to manage the portfolio. The stability of these margins suggests that the core business model is well-insulated from inflationary pressures on physical goods or labor.

Non-Operating Items Distort Net Income

Based on reported figures, XOMA's net income exhibits extreme volatility, with quarterly swings from a $20.1M loss in 2023Q4 to a $16.0M profit in 2024Q2, suggesting that reported earnings are heavily influenced by non-operating items, fair value adjustments, and potential tax asset utilization rather than core operational performance.

The lack of correlation between operating income and net income warrants further investigation into the nature of these non-operating gains and losses. Analysts should be cautious in using GAAP net income as a proxy for cash-generating ability, as these accounting adjustments may mask the underlying burn rate of the business.

Fixed G&A Costs Constrain Profitability

As indicated by the income statement data, XOMA's SG&A expenses remain consistently high relative to revenue, often exceeding $8M to $10M per quarter, which suggests that the company's fixed cost structure requires a higher and more consistent revenue base to achieve sustainable, long-term operating leverage.

The inability to scale SG&A efficiently against lumpy revenue streams creates periods of significant operating losses. Management's expense discipline appears focused on maintaining the infrastructure for portfolio management, but this fixed-cost burden remains a primary headwind to achieving consistent operating profitability.

Binary Risk of Clinical Attrition

While the portfolio approach is intended to mitigate risk, the concentration of assets in Phase 1 and 2, as noted in company intelligence, suggests that the income statement remains vulnerable to high clinical attrition rates that could permanently impair the value of future royalty streams.

Short-term revenue spikes may distract from the reality that the majority of the underlying assets may never reach commercialization. Investors should monitor the clinical success rates of the partner programs, as a failure to advance these assets will eventually lead to a depletion of the milestone pipeline.

XOMAP — Frequently Asked Questions

Quick answers to the most common questions about buying XOMAP stock.

What was XOMA Corporation's (XOMAP) revenue in 2025?

For fiscal year 2025, XOMA Corporation (XOMAP) reported total revenue of $52.1M. This represents a 1348.6% increase compared to $3.6M in 1996.

Is XOMA Corporation (XOMAP) profitable?

XOMA Corporation (XOMAP) is profitable, generating $31.7M in net income for the fiscal year ending 2025 with a net profit margin of 60.8%.

What is XOMA Corporation's operating profit margin?

XOMA Corporation (XOMAP) reported an operating income of $11.4M, resulting in an operating profit margin of 21.8%. This margin reflects the operational efficiency of the business before interest and taxes.

What is XOMA Corporation's gross profit and gross margin?

XOMA Corporation (XOMAP) generated $49.2M in gross profit for the year, representing a gross profit margin of 94.3%. This demonstrates the company's core pricing power and production efficiency.